Additive systems for use in protein PEGylation

Patent metadata

Field	Value
Publication number	US-11213589-B2
Application number	US-202016797361-A
Country	US
Kind code	B2
Filing date	Feb 21, 2020
Priority date	Nov 23, 2015
Publication date	Jan 4, 2022
Grant date	Jan 4, 2022

Abstract

The present disclosure provides an additive system for use in protein PEGylation. The additive system includes p-aminobenzoic hydrazide used either alone or in combination with aromatic amines, such as 3,5-diaminobenzoic acid, or with ammonium salts such as ammonium chloride or ammonium acetate. The disclosed additive combination provides several benefits including increased reaction rates, higher yields and reduction in the aminoxy-PEG equivalents required to complete the conjugation reaction. Typical reactions can be run by combining the additive or additive system with a solution of a protein and aminoxy-PEG reagent. The solution is adjusted to pH 4 and held at 20-25° C. without stirring until completion, typically within 24 hours.

First claim

We claim:

1. A process for obtaining PEGylated FGF21 protein, the process comprising a step of reacting FGF21 protein with a PEG reagent in presence of an additive system to obtain PEGylated FGF21 protein, wherein the additive system includes p-aminobenzoic hydrazide and wherein the PEG reagent is selected from a group consisting of PEG-oxyamine and other PEG derivatives with an aminoxy group.

2. The process of claim 1 , wherein the FGF21 protein carries a p-acetylphenylalanine residue.

3. The process of claim 2 , wherein the PEG reagent has the structure of formula (I)

4. The process of claim 3 , wherein the PEGylated FGF21 protein has the structure of formula (II)

5. The process of claim 4 , wherein the FGF21 protein is reacted with the PEG reagent in the presence of the additive system at a pH of about 4.

6. The process of claim 4 , wherein the FGF21 protein is reacted with the PEG reagent in the presence of the additive system at a temperature ranging from about 20° C. to about 25° C.

7. The process of claim 2 , wherein the FGF21 protein is reacted with the PEG reagent in the presence of the additive system at a pH of about 4.

8. The process of claim 2 , wherein the FGF21 protein is reacted with the PEG reagent in the presence of the additive system at a temperature ranging from about 20° C. to about 25° C.

9. The process of claim 1 , wherein the additive system includes p-aminobenzoic hydrazide in combination with an aromatic amine, such as 3,5-diaminobenzoic acid, or in combination with an ammonium salt, such as ammonium acetate or ammonium chloride.

10. The process of claim 4 , wherein the FGF21 protein is solubilized prior to reacting the FGF21 protein with the PEG reagent in the presence of the additive system.

11. The process of claim 2 , wherein the FGF21 protein is solubilized prior to reacting the FGF21 protein with the PEG reagent in the presence of the additive system.

12. The process of claim 10 , wherein the FGF21 protein is solubilized in urea prior to reacting the FGF21 protein with the PEG reagent in the presence of the additive system.

13. The process of claim 11 , wherein the FGF21 protein is solubilized in urea prior to reacting the FGF21 protein with the PEG reagent in the presence of the additive system.

Assignees

• Bristol Myers Squibb Co

Inventors

• Hickey Matthew R
• Ramirez Antonio

Classifications

• A61K47/60 Primary

  the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title

• C07K14/64

  Relaxins · CPC title

• C07K14/50

  Fibroblast growth factor [FGF] · CPC title

• C07K1/1077 Primary

  by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids · CPC title